I
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com. For U.S. residents only.
Investor insights
Funding rounds participated in
$450M sweet spot round size
Investor type
Public Company
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
2018
Funding rounds raised
Total raised
$450M
from 1 investors over 1 rounds
I
Immunovant raised $450M on February 13, 2025
Investors: Roivant Sciences